We’re thrilled to announce that @ModuloBio has secured a $4.8M strategic investment from the @TheADDF ! This funding will accelerate the development of our novel CSF1R inhibitor targeting Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS).

This investment is a powerful validation of our mission to reprogram the brain's immune system to combat neurodegenerative diseases.

Our approach focuses on modulating microglial cells, the brain's primary immune cells, which play a crucial role in neuroinflammation and disease progression.

This funding will support IND-enabling studies and bring our CSF1R inhibitor closer to clinical trials. We're incredibly proud of our team's work and grateful for @TheADDF's belief in our vision to deliver new hope to patients with devastating neurodegenerative conditions.